000 | 01930 a2200565 4500 | ||
---|---|---|---|
005 | 20250518091227.0 | ||
264 | 0 | _c20200907 | |
008 | 202009s 0 0 eng d | ||
022 | _a1539-3704 | ||
024 | 7 |
_a10.7326/M19-0735 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aPleguezuelos, Olga | |
245 | 0 | 0 |
_aImmunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults: A Randomized Clinical Trial. _h[electronic resource] |
260 |
_bAnnals of internal medicine _c04 2020 |
||
300 |
_a453-462 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAntibodies, Viral _xblood |
650 | 0 | 4 | _aDose-Response Relationship, Immunologic |
650 | 0 | 4 | _aDouble-Blind Method |
650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFlow Cytometry |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aImmunity, Cellular |
650 | 0 | 4 |
_aInfluenza Vaccines _xadverse effects |
650 | 0 | 4 |
_aInfluenza, Human _xprevention & control |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aNetherlands |
650 | 0 | 4 | _aPatient Safety |
650 | 0 | 4 |
_aVaccines, Synthetic _xadverse effects |
700 | 1 | _aDille, Joep | |
700 | 1 | _ade Groen, Sofie | |
700 | 1 | _aOftung, Fredrik | |
700 | 1 | _aNiesters, Hubert G M | |
700 | 1 | _aIslam, Md Atiqul | |
700 | 1 | _aNæss, Lisbeth Meyer | |
700 | 1 | _aHungnes, Olav | |
700 | 1 | _aAldarij, Nuhoda | |
700 | 1 | _aIdema, Demi L | |
700 | 1 | _aPerez, Ana Fernandez | |
700 | 1 | _aJames, Emma | |
700 | 1 | _aFrijlink, Henderik W | |
700 | 1 | _aStoloff, Gregory | |
700 | 1 | _aGroeneveld, Paul | |
700 | 1 | _aHak, Eelko | |
773 | 0 |
_tAnnals of internal medicine _gvol. 172 _gno. 7 _gp. 453-462 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.7326/M19-0735 _zAvailable from publisher's website |
999 |
_c30721289 _d30721289 |